GB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles
First of their kind, myrcene nanoparticles are central to a novel, time-released therapeutic for neuropathic pain
LAS VEGAS, Nov. 20, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) and the Universidad de Sevilla (USE) announce the filing of a provisional patent application on the creation of myrcene-containing nanoparticles for use in the treatment of neuropathic pain.
"We have achieved a significant research milestone in the creation of the myrcene-containing nanoparticles that are at the core of our patent-pending, myrcene-based complex mixtures for the treatment of neuropathic pain," said Dr. Andrea Small-Howard. "Our colleagues at the Universidad de Sevilla had to overcome serious physical and chemical challenges to stabilize the very small myrcene molecules that are prone to evaporating. USE is also creating nanoparticle versions of the other compounds in our myrcene-containing complex mixtures; however, these other terpenoids and cannabinoids should not be as challenging because they are bigger, and USE has discovered ways to stabilize small molecules, like myrcene."
Back in October of 2017, GB Sciences, Inc. entered into a Contract Research Agreement with the Universidad de Sevilla to develop a time-released version of GB Sciences' proprietary, THC-free, myrcene-based chronic pain formulations, which contain a mixture of terpenoids and cannabinoids. USE researchers have created a prototype of the myrcene-containing nanoparticles, and GB and USE will begin functional testing of these formulations.
"We are so pleased to be working with GB Sciences on this very important project that has such potential to help people with neuropathic pain," said Dr. Mercedes Fernández Arévalo (I+DNanomed, Website: grupos.us.es/idnanomed/). "Our research group has been diligently working on the development of new oral drug delivery systems to enhance the bioavailability of lipophilic molecules such as cannabinoids, and now, terpenoids." Dr. Lucía Martín Banderas, I+DNanomed nanotech researcher at USE, said, "We believe that this may be the first terpenoid-nanoparticle ever created."
John Poss, CEO and Chairman of GB Sciences, says: "We are proud to be collaborating with world-class nanotechnology researchers at the University of Seville. Together, we will work to bring a new class of cannabis-based medicines through developmental processes, including clinical trials registered with the US FDA, to bring much needed options for the treatment of neuropathic pain."
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
About Universidad de Sevilla
Universidad de Sevilla (USE) is an institution with more than five centuries of history, with an accredited academic tradition, and with recognition as an International Campus of Excellence. All of our qualifications are adapted to the European Higher Education Area and cover all areas of knowledge that provide a public higher education service through study, teaching and research, as well as the generation, development and dissemination of knowledge at the service of Society and Citizenship. USE has made an important effort to improve its research facilities and scientific equipment, which has made it possible to be a Center for Research Excellence that answers public calls for research, engages in collaborations with companies, and creates an important patent portfolio. Our Campus model is integrated in to the city of Sevilla, unfolding in several urban areas and contributing to the vibrancy of the city. www.us.es
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
Corporate:
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Tom Arcuragi, EVP, [email protected]
SOURCE GB Sciences, Inc.
Share this article